

EDWARDS LIFESCIENCES CORPORATION
Reconciliation of GAAP to Non-GAAP Financial Information

(in millions, except per share data)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
GAAP net income	\$32.9	\$29.1	\$90.8	\$97.2
Reconciling items:				
Special (gains) charges, net				
1) Loss on sale of product line	-	-	8.1	-
2) Litigation settlement	-	-	2.1	-
3) Realignment expenses, net	-	-	(0.9)	-
4) Gain on estimated insurance settlement	-	(2.5)	-	(2.5)
Total special (gains) charges, net	-	(2.5)	9.3	(2.5)
Provision for income taxes				
Tax effect on non-GAAP adjustments (A)	-	1.0	5.0	1.0
Total provision for income taxes, net	-	1.0	5.0	1.0
Non-GAAP net income	\$32.9	\$27.6	\$105.1	\$95.7
Non-GAAP earnings per share:				
Basic non-GAAP earnings per share	\$0.59	\$0.48	\$1.88	\$1.66
Diluted non-GAAP earnings per share (B)	\$0.56	\$0.46	\$1.78	\$1.57
Non-GAAP weighted average shares outstanding:				
Basic	56.0	57.1	55.8	57.5
Diluted	59.0	62.4	60.1	63.0

Notes 1 - 4: See description of Special (Gains) Charges, net on the previous page.

(A) The tax effect on non-GAAP adjustments is calculated using the relevant tax jurisdictions' statutory tax rates.

(B) Diluted non-GAAP earnings per share is calculated by adding back to net income \$1.7 million for the nine month period in interest expense related to the convertible debt, then dividing by the weighted average diluted shares outstanding.

Note: Numbers may not calculate due to rounding